Athenex appoints darrel p. cohen, md, phd as chief medical officer of cell therapy

Buffalo, n.y., june 08, 2022 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of darrel p. cohen, md, phd as chief medical officer of cell therapy to lead its clinical development, clinical operations, and regulatory affairs functions. he will be replacing kurt gunter, md, who has decided to pursue other opportunities outside of cell therapy.
ATNX Ratings Summary
ATNX Quant Ranking